The Latest Cardiac and Vascular News
MENLO PARK, Calif., June 22, 2021 /PRNewswire/ — Ablacon, Inc., developer of an advanced mapping system to guide the treatment of atrial fibrillation (AF), announced today that is has promoted Martin Grasse to the position of Chief Executive Officer. Former CEO Duke Rohlen will continue with the […]
Zeus Health joins as new lead investor and Dr. David Haines is added to SAB MENLO PARK, Calif., Jan. 7, 2021 /PRNewswire/ — Ablacon, Inc., an Ajax Health-backed company, announced the close of a $30 million Series B financing, with Zeus Health joining as new […]
Scientific advisory board composed of thought leaders in electrophysiology and treatment of atrial fibrillation MENLO PARK, Calif., June 23, 2020 /PRNewswire/ — Ablacon, Inc., an Ajax Health-backed company, announced today the formation of its Scientific Advisory Board (SAB). The SAB will be composed of […]
MENLO PARK, Calif., Sept. 10, 2019 /PRNewswire/ — Ablacon, Inc. (www.ablacon.com), an Ajax Health-funded company, announced today the release of an updated version of its Ablamap technology under the company’s existing CE Mark. The new update includes an enhanced physician experience and user […]
MENLO PARK, Calif., July 23, 2019 /PRNewswire/ — Ablacon Inc. announced today that it has entered into a $10 millionventure debt facility with Western Technology Investment (WTI). The debt is accompanied by a $2 million equity investment in the Company. This financing will help fund Ablacon’s […]
MENLO PARK, Calif., April 30, 2019 /PRNewswire/ — Ablacon, Inc. (www.ablacon.com), a Wheat Ridge, CO-based company developing an advanced mapping system to guide the treatment of atrial fibrillation (AFib), today announced the closing of a $21.5 million Series A financing round led by Ajax Health. Ablacon’s […]
